annual CFF:
-$2.20B-$410.40M(-22.93%)Summary
- As of today (June 3, 2025), REGN annual cash flow from financing activities is -$2.20 billion, with the most recent change of -$410.40 million (-22.93%) on December 31, 2024.
- During the last 3 years, REGN annual CFF has fallen by -$1.19 billion (-118.78%).
- REGN annual CFF is now -672.68% below its all-time high of $384.25 million, reached on December 31, 2011.
Performance
REGN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$1.09B+$46.30M(+4.08%)Summary
- As of today (June 3, 2025), REGN quarterly cash flow from financing activities is -$1.09 billion, with the most recent change of +$46.30 million (+4.08%) on March 31, 2025.
- Over the past year, REGN quarterly CFF has dropped by -$1.14 billion (-2412.53%).
- REGN quarterly CFF is now -277.97% below its all-time high of $612.00 million, reached on September 30, 2020.
Performance
REGN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$3.34B-$1.14B(-51.64%)Summary
- As of today (June 3, 2025), REGN TTM cash flow from financing activities is -$3.34 billion, with the most recent change of -$1.14 billion (-51.64%) on March 31, 2025.
- Over the past year, REGN TTM CFF has dropped by -$1.92 billion (-134.90%).
- REGN TTM CFF is now -968.40% below its all-time high of $384.25 million, reached on December 31, 2011.
Performance
REGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
REGN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -22.9% | -2412.5% | -134.9% |
| 3 y3 years | -118.8% | -1783.5% | -480.6% |
| 5 y5 years | -772.9% | -424.6% | -9067.0% |
REGN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -118.8% | at low | -1783.5% | +4.1% | -498.4% | at low |
| 5 y | 5-year | -772.9% | at low | -278.0% | +58.3% | -9067.0% | at low |
| alltime | all time | -672.7% | at low | -278.0% | +58.3% | -968.4% | at low |
REGN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$1.09B(-4.1%) | -$3.34B(+51.6%) |
| Dec 2024 | -$2.20B(+22.9%) | -$1.14B(+79.1%) | -$2.20B(+45.6%) |
| Sep 2024 | - | -$634.00M(+32.6%) | -$1.51B(+17.7%) |
| Jun 2024 | - | -$478.10M(-1115.1%) | -$1.28B(-9.6%) |
| Mar 2024 | - | $47.10M(-110.6%) | -$1.42B(-20.6%) |
| Dec 2023 | -$1.79B(+77.4%) | -$446.10M(+9.5%) | -$1.79B(+12.5%) |
| Sep 2023 | - | -$407.30M(-33.7%) | -$1.59B(-16.6%) |
| Jun 2023 | - | -$614.20M(+90.4%) | -$1.91B(+36.7%) |
| Mar 2023 | - | -$322.50M(+30.3%) | -$1.40B(+38.4%) |
| Dec 2022 | -$1.01B(+0.3%) | -$247.60M(-65.8%) | -$1.01B(-39.5%) |
| Sep 2022 | - | -$725.00M(+617.1%) | -$1.67B(+199.1%) |
| Jun 2022 | - | -$101.10M(-256.3%) | -$557.60M(-3.0%) |
| Mar 2022 | - | $64.70M(-107.1%) | -$574.70M(-42.9%) |
| Dec 2021 | -$1.01B(-49.0%) | -$906.60M(-335.2%) | -$1.01B(+148.7%) |
| Sep 2021 | - | $385.40M(-426.1%) | -$404.50M(+127.4%) |
| Jun 2021 | - | -$118.20M(-67.7%) | -$177.90M(-93.3%) |
| Mar 2021 | - | -$366.40M(+20.0%) | -$2.67B(+35.6%) |
| Dec 2020 | -$1.97B(+681.6%) | -$305.30M(-149.9%) | -$1.97B(-2.0%) |
| Sep 2020 | - | $612.00M(-123.4%) | -$2.01B(-23.7%) |
| Jun 2020 | - | -$2.61B(-878.5%) | -$2.63B(+7136.0%) |
| Mar 2020 | - | $335.60M(-197.1%) | -$36.40M(-85.6%) |
| Dec 2019 | -$252.10M(+227.0%) | -$345.70M(+3042.7%) | -$252.10M(-2478.3%) |
| Sep 2019 | - | -$11.00M(-28.1%) | $10.60M(-58.1%) |
| Jun 2019 | - | -$15.30M(-112.8%) | $25.30M(-13.9%) |
| Mar 2019 | - | $119.90M(-244.5%) | $29.40M(-138.1%) |
| Dec 2018 | -$77.10M(+216.0%) | -$83.00M(-2343.2%) | -$77.10M(-62.3%) |
| Sep 2018 | - | $3.70M(-133.0%) | -$204.63M(-5.5%) |
| Jun 2018 | - | -$11.20M(-183.6%) | -$216.53M(+201.5%) |
| Mar 2018 | - | $13.40M(-106.4%) | -$71.81M(+194.3%) |
| Dec 2017 | -$24.40M(-96.5%) | -$210.53M(+2468.8%) | -$24.40M(-92.0%) |
| Sep 2017 | - | -$8.20M(-106.1%) | -$305.65M(+13.7%) |
| Jun 2017 | - | $133.52M(+119.6%) | -$268.78M(-38.0%) |
| Mar 2017 | - | $60.81M(-112.4%) | -$433.50M(-38.1%) |
| Dec 2016 | -$700.50M(+166.6%) | -$491.79M(-1815.0%) | -$700.50M(+229.3%) |
| Sep 2016 | - | $28.68M(-191.9%) | -$212.72M(-63.8%) |
| Jun 2016 | - | -$31.20M(-84.9%) | -$587.04M(+4.9%) |
| Mar 2016 | - | -$206.19M(+5044.5%) | -$559.38M(+112.9%) |
| Dec 2015 | -$262.80M(+20.2%) | -$4.01M(-98.8%) | -$262.80M(-48.6%) |
| Sep 2015 | - | -$345.65M(+9677.9%) | -$511.44M(+218.4%) |
| Jun 2015 | - | -$3.54M(-103.9%) | -$160.63M(-32.3%) |
| Mar 2015 | - | $90.40M(-135.8%) | -$237.10M(+8.5%) |
| Dec 2014 | -$218.55M(-402.7%) | -$252.66M(-4990.7%) | -$218.55M(-262.2%) |
| Sep 2014 | - | $5.17M(-106.5%) | $134.72M(+1.2%) |
| Jun 2014 | - | -$80.01M(-173.4%) | $133.09M(-21.5%) |
| Mar 2014 | - | $108.95M(+8.3%) | $169.62M(+135.0%) |
| Dec 2013 | $72.19M(-173.9%) | $100.62M(+2747.9%) | $72.19M(-171.2%) |
| Sep 2013 | - | $3.53M(-108.1%) | -$101.44M(-5.0%) |
| Jun 2013 | - | -$43.48M(-477.3%) | -$106.78M(+56.2%) |
| Mar 2013 | - | $11.52M(-115.8%) | -$68.37M(-30.0%) |
| Dec 2012 | -$97.65M(-125.4%) | -$73.01M(+3935.9%) | -$97.65M(-129.0%) |
| Sep 2012 | - | -$1.81M(-64.4%) | $336.80M(-0.5%) |
| Jun 2012 | - | -$5.08M(-71.4%) | $338.33M(-4.3%) |
| Mar 2012 | - | -$17.75M(-104.9%) | $353.46M(-8.0%) |
| Dec 2011 | $384.25M(+57.9%) | $361.44M(<-9900.0%) | $384.25M(+86.9%) |
| Sep 2011 | - | -$279.00K(-102.8%) | $205.57M(-0.9%) |
| Jun 2011 | - | $10.05M(-22.9%) | $207.46M(+3.7%) |
| Mar 2011 | - | $13.04M(-92.9%) | $200.13M(-17.7%) |
| Dec 2010 | $243.31M(+675.8%) | $182.76M(>+9900.0%) | $243.31M(+193.6%) |
| Sep 2010 | - | $1.61M(-40.7%) | $82.88M(-0.6%) |
| Jun 2010 | - | $2.72M(-95.2%) | $83.41M(+2.5%) |
| Mar 2010 | - | $56.22M(+151.8%) | $81.36M(+159.4%) |
| Dec 2009 | $31.36M(-116.3%) | $22.33M(+939.5%) | $31.36M(-129.4%) |
| Sep 2009 | - | $2.15M(+222.0%) | -$106.68M(-0.8%) |
| Jun 2009 | - | $667.00K(-89.3%) | -$107.51M(-43.0%) |
| Mar 2009 | - | $6.22M(-105.4%) | -$188.54M(-2.2%) |
| Dec 2008 | -$192.86M | -$115.72M(-8840.1%) | -$192.86M(-181.3%) |
| Sep 2008 | - | $1.32M(-101.6%) | $237.09M(+0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$80.37M(-4323.1%) | $236.11M(-26.1%) |
| Mar 2008 | - | $1.90M(-99.4%) | $319.35M(-0.0%) |
| Dec 2007 | $319.40M(+72.3%) | $314.23M(>+9900.0%) | $319.40M(+72.4%) |
| Sep 2007 | - | $347.00K(-87.9%) | $185.30M(-0.4%) |
| Jun 2007 | - | $2.87M(+46.4%) | $186.02M(+1.1%) |
| Mar 2007 | - | $1.96M(-98.9%) | $183.94M(-0.8%) |
| Dec 2006 | $185.40M(+4443.0%) | $180.13M(>+9900.0%) | $185.40M(+2152.2%) |
| Sep 2006 | - | $1.07M(+36.0%) | $8.23M(+13.5%) |
| Jun 2006 | - | $787.00K(-77.0%) | $7.25M(+12.1%) |
| Mar 2006 | - | $3.42M(+15.4%) | $6.47M(+58.5%) |
| Dec 2005 | $4.08M(-8.1%) | $2.96M(+3187.8%) | $4.08M(+110.3%) |
| Sep 2005 | - | $90.00K(+4400.0%) | $1.94M(+86.1%) |
| Jun 2005 | - | $2000.00(-99.8%) | $1.04M(-23.9%) |
| Mar 2005 | - | $1.03M(+25.8%) | $1.37M(-69.2%) |
| Dec 2004 | $4.44M(-95.9%) | $819.00K(-201.4%) | $4.44M(-45.9%) |
| Sep 2004 | - | -$808.00K(-345.6%) | $8.21M(-86.0%) |
| Jun 2004 | - | $329.00K(-92.0%) | $58.54M(-8.2%) |
| Mar 2004 | - | $4.10M(-10.6%) | $63.79M(-41.0%) |
| Dec 2003 | $108.18M(+6178.8%) | $4.59M(-90.7%) | $108.18M(+3.8%) |
| Sep 2003 | - | $49.52M(+788.1%) | $104.19M(+90.8%) |
| Jun 2003 | - | $5.58M(-88.5%) | $54.62M(+11.1%) |
| Mar 2003 | - | $48.50M(+8064.5%) | $49.16M(+2753.3%) |
| Dec 2002 | $1.72M(-99.5%) | $594.00K(-1337.5%) | $1.72M(-99.1%) |
| Sep 2002 | - | -$48.00K(-140.0%) | $192.41M(-0.2%) |
| Jun 2002 | - | $120.00K(-88.6%) | $192.85M(-1.6%) |
| Mar 2002 | - | $1.06M(-99.4%) | $196.03M(-43.9%) |
| Dec 2001 | $349.12M(+275.9%) | $191.28M(>+9900.0%) | $349.12M(+121.4%) |
| Sep 2001 | - | $398.00K(-87.9%) | $157.68M(-9.8%) |
| Jun 2001 | - | $3.29M(-97.9%) | $174.84M(-28.4%) |
| Mar 2001 | - | $154.15M(<-9900.0%) | $244.34M(+163.1%) |
| Dec 2000 | $92.87M(>+9900.0%) | -$161.00K(-100.9%) | $92.87M(-0.4%) |
| Sep 2000 | - | $17.55M(-75.9%) | $93.23M(+23.7%) |
| Jun 2000 | - | $72.80M(+2621.4%) | $75.37M(+3073.6%) |
| Mar 2000 | - | $2.67M(+1237.5%) | $2.38M(+691.7%) |
| Dec 1999 | $300.00K(-121.4%) | $200.00K(-166.7%) | $300.00K(-250.0%) |
| Sep 1999 | - | -$300.00K(+50.0%) | -$200.00K(0.0%) |
| Jun 1999 | - | -$200.00K(-133.3%) | -$200.00K(-33.3%) |
| Mar 1999 | - | $600.00K(-300.0%) | -$300.00K(-78.6%) |
| Dec 1998 | -$1.40M(-103.6%) | -$300.00K(0.0%) | -$1.40M(-36.4%) |
| Sep 1998 | - | -$300.00K(0.0%) | -$2.20M(-15.4%) |
| Jun 1998 | - | -$300.00K(-40.0%) | -$2.60M(-106.5%) |
| Mar 1998 | - | -$500.00K(-54.5%) | $39.90M(+1.3%) |
| Dec 1997 | $39.40M(-40.6%) | -$1.10M(+57.1%) | $39.40M(-21.2%) |
| Sep 1997 | - | -$700.00K(-101.7%) | $50.00M(+0.4%) |
| Jun 1997 | - | $42.20M(-4320.0%) | $49.80M(-23.5%) |
| Mar 1997 | - | -$1.00M(-110.5%) | $65.10M(-1.8%) |
| Dec 1996 | $66.30M(+233.2%) | $9.50M(-1155.6%) | $66.30M(-15.6%) |
| Sep 1996 | - | -$900.00K(-101.6%) | $78.60M(-0.3%) |
| Jun 1996 | - | $57.50M(>+9900.0%) | $78.80M(+282.5%) |
| Mar 1996 | - | $200.00K(-99.1%) | $20.60M(+3.5%) |
| Dec 1995 | $19.90M(<-9900.0%) | $21.80M(-3214.3%) | $19.90M(-5075.0%) |
| Sep 1995 | - | -$700.00K(0.0%) | -$400.00K(0.0%) |
| Jun 1995 | - | -$700.00K(+40.0%) | -$400.00K(-20.0%) |
| Mar 1995 | - | -$500.00K(-133.3%) | -$500.00K(+150.0%) |
| Dec 1994 | -$200.00K(-100.4%) | $1.50M(-314.3%) | -$200.00K(-91.3%) |
| Sep 1994 | - | -$700.00K(-12.5%) | -$2.30M(-104.7%) |
| Jun 1994 | - | -$800.00K(+300.0%) | $49.40M(-1.0%) |
| Mar 1994 | - | -$200.00K(-66.7%) | $49.90M(+0.2%) |
| Dec 1993 | $49.80M(-6325.0%) | -$600.00K(-101.2%) | $49.80M(-0.8%) |
| Sep 1993 | - | $51.00M(<-9900.0%) | $50.20M(-4663.6%) |
| Jun 1993 | - | -$300.00K(0.0%) | -$1.10M(+10.0%) |
| Mar 1993 | - | -$300.00K(+50.0%) | -$1.00M(+25.0%) |
| Dec 1992 | -$800.00K(-100.9%) | -$200.00K(-33.3%) | -$800.00K(+33.3%) |
| Sep 1992 | - | -$300.00K(+50.0%) | -$600.00K(+100.0%) |
| Jun 1992 | - | -$200.00K(+100.0%) | -$300.00K(+200.0%) |
| Mar 1992 | - | -$100.00K | -$100.00K |
| Dec 1991 | $91.50M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual CFF year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?
- What is Regeneron Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM CFF year-on-year change?
What is Regeneron Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of REGN is -$2.20B
What is the all time high annual CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash flow from financing activities is $384.25M
What is Regeneron Pharmaceuticals annual CFF year-on-year change?
Over the past year, REGN annual cash flow from financing activities has changed by -$410.40M (-22.93%)
What is Regeneron Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of REGN is -$1.09B
What is the all time high quarterly CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash flow from financing activities is $612.00M
What is Regeneron Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, REGN quarterly cash flow from financing activities has changed by -$1.14B (-2412.53%)
What is Regeneron Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of REGN is -$3.34B
What is the all time high TTM CFF for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM cash flow from financing activities is $384.25M
What is Regeneron Pharmaceuticals TTM CFF year-on-year change?
Over the past year, REGN TTM cash flow from financing activities has changed by -$1.92B (-134.90%)